首页> 外文期刊>Journal of Molecular Biology >Crystal structure of the catalytic domain of human atypical protein kinase C-iota reveals interaction mode of phosphorylation site in turn motif
【24h】

Crystal structure of the catalytic domain of human atypical protein kinase C-iota reveals interaction mode of phosphorylation site in turn motif

机译:人类非典型蛋白激酶C-iota催化结构域的晶体结构揭示了磷酸化位点的相互作用模式

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Atypical protein kinases C (aPKCs) play critical roles in signaling pathways that control cell growth, differentiation and survival. Therefore, they constitute attractive targets for the development of novel therapeutics against cancer. The crystal structure of the catalytic domain of atypical PKCl in complex with the bis(indolyl)maleimide inhibitor BIM1 has been determined at 3.0 angstrom resolution within the frame of the European Structural Proteomics Project SPINE. The overall structure exhibits the classical bilobal kinase fold and is in its fully activated form. Both phosphorylation sites (Thr403 in the activation loop, and Thr555 in the turn motif) are well defined in the structure and form intramolecular ionic contacts that make an important contribution in stabilizing the active conformation of the catalytic subunit. The phosphorylation site in the hydrophobic motif of atypical PKCs is replaced by the phosphorylation mimic glutamate and this is also clearly seen in the structure of PKCl (residue 574). This structure determination for the first time provides the architecture of the turn motif phosphorylation site, which is characteristic for PKCs and PKB/AKT, and is completely different from that in PKA. The bound BIM1 inhibitor blocks the ATP-binding site and puts the kinase domain into an intermediate open conformation. The PKCl-BIM1 complex is the first kinase domain crystal structure of any atypical PKC and constitutes the basis for rational drug design for selective PKCl inhibitors. (c) 2005 Elsevier Ltd. All rights reserved.
机译:非典型蛋白激酶C(aPKC)在控制细胞生长,分化和存活的信号传导途径中起关键作用。因此,它们构成开发抗癌新疗法的有吸引力的靶标。与双(吲哚基)马来酰亚胺抑制剂BIM1配合使用的非典型PKCl催化结构域的晶体结构已在欧洲结构蛋白质组学计划SPINE框架内以3.0埃的分辨率确定。整体结构表现出经典的双叶激酶折叠,并且处于其完全活化的形式。两个磷酸化位点(激活环中的Thr403和转向基序中的Thr555)在结构中均得到很好的定义,并形成分子内离子接触,这对稳定催化亚基的活性构象起了重要作用。非典型PKCs的疏水基序中的磷酸化位点被谷氨酸的磷酸化取代,这在PKC1的结构中也清楚可见(残基574)。这种结构确定首次提供了转位基序磷酸化位点的结构,这是PKC和PKB / AKT的特征,与PKA中的完全不同。结合的BIM1抑制剂可阻断ATP结合位点,并使激酶结构域处于中间开放构象。 PKC1-BIM1复合物是任何非典型PKC的第一个激酶结构域晶体结构,并且构成选择性PKC1抑制剂合理药物设计的基础。 (c)2005 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号